Bristol-Myers beefs up cancer portfolio with $74 billion Celgene buy

Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion, creating a pharma company with several blockbuster cancer drugs and making it one of the biggest mergers on record in the sector.

…read more

Discover Tomorrow’s Winning Stocks!
Get our latest stock reports before everyone else! Actionable news, and breakout stocks w multi-bagger upside potential — delivered directly to your inbox.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

Source:: Reuters – Business News